Pediatric rhabdomyosarcoma with bone marrow metastasis
- 26 February 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (5) , e28219
Abstract
Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of adolescence and childhood. Although most patients with localized RMS are cured, outcome of those with metastatic disease remains unsatisfactory. RMS with bone marrow (BM) metastasis accounts for approximately 6% of all cases with RMS and has a 3‐year event‐free survival of 14%. Our study aims to describe our institution's experience of patients with metastatic RMS with BM involvement.Methods: This was a single‐institution retrospective study from Memorial Sloan Kettering Kids, a tertiary pediatric oncology center. Patients with RMS who were diagnosed with BM metastasis between 1998 and 2018 were identified from pathology reports.Results: For patients with RMS and BM positivity at diagnosis (N = 27), the median survival was 1.5 years. The 1‐, 2‐, and 3‐year overall survival (OS) were 81%, 32%, and 20%, respectively. There is one long‐term (defined as >4 year) survivor who is still alive 14.9 years after diagnosis despite two metastatic recurrences. An Oberlin status of 4 that included BM metastasis portended a 3‐year OS of 0%.Conclusions: Although most patients will respond to initial therapy, BM metastasis at the time of diagnosis lends a near‐fatal diagnosis in pediatric patients with RMS. Novel therapies are desperately needed to consolidate their initial remission.Keywords
Funding Information
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
This publication has 24 references indexed in Scilit:
- Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma CommitteeJournal of Clinical Oncology, 2013
- Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study GroupPediatric Blood & Cancer, 2010
- Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcomaEuropean Journal of Cancer, 2009
- A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric SarcomasClinical Cancer Research, 2008
- Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative GroupsJournal of Clinical Oncology, 2008
- Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter TrialJournal of Clinical Oncology, 2007
- Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markersCancer, 2006
- Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assayJournal of Cancer Research and Clinical Oncology, 2006
- PAX3-FKHR and PAX7-FKHR Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2002
- Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective european multi‐center analysisMedical and Pediatric Oncology, 1992